1991 - 2000 of 4301 Drugs
Emcyt (estramustine)
Emcyt (estramustine phosphate sodium) is an antineoplastic (anti-cancer) drug used to treat prostate cancer.
Emend Injection (fosaprepitant dimeglumine injection)
Emend (fosaprepitant dimeglumine injection) is a substance P/neurokinin-1 (NK1) receptor antagonist that works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting and is used together with other medications to prevent nausea and vomiting that may be caused by cancer chemotherapy. Emend is given ahead of time and will not treat nausea or vomiting that is already present.
Emerphed (ephedrine sulfate injection)
Emerphed (ephedrine sulfate) is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent used to treat clinically important low blood pressure (hypotension) occurring in the setting of anesthesia.
Emgality (galcanezumab-gnlm injection)
Emgality (galcanezumab-gnlm) is a calcitonin-gene related peptide antagonist indicated for the preventive treatment of migraine in adults.
Emgel (erythromycin)
Emgel (erythromycin) Topical Gel is an antibiotic used to treat bacterial infections such as severe acne. The brand name Emgel is discontinued, but generic versions may be available.
Hemlibra (emicizumab-kxwh injection, for subcutaneous use)
Hemlibra (emicizumab-kxwh) injection is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
Emla (lidocaine and prilocaine)
Emla (lidocaine 2.5% and prilocaine 2.5%) Cream is a topical anesthetic for use on normal intact skin for local analgesia of intact skin and to prevent pain associated with IV cannulation, needle insertion, and superficial surgery on skin and genital mucous membranes.
Glyxambi (empagliflozin and linagliptin tablets)
Glyxambi (empagliflozin and linagliptin) is a combination of an inhibitor of the sodium-glucose co-transporter (SGLT2) and an inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Synjardy XR Extended-release Tablets (empagliflozin and metformin hydrochloride extended-release)
Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets, for oral use is a combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate.
Synjardy (empagliflozin and metformin hydrochloride tablets)
Synjardy (empagliflozin and metformin hydrochloride) is a combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. Synjardy is not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.